跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
KESIMPTA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
KESIMPTA
Authorized
STANDARD
KESIMPTA
novartis pharmaceuticals canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
7424440cb1104de5
Company
novartis pharmaceuticals canada inc
Type
Standard
Approval Details
Approval Id
7424440cb1104de5
Drug Approval Canada Name
KESIMPTA
Product Name
KESIMPTA
Status
Marketed
Status Date
2021-04-08
Original Market Date
2021-04-08
Din
02511355
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
92:20.00
Atc Original
L04AG12 OFATUMUMAB
Atc Name
l 04 ag 12
Aig Number
0153129002
Company Name
novartis pharmaceuticals canada inc
Company Address
100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1
Active Ingredients
OFATUMUMAB
20 MG / 0.4 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
7424440cb1104de5
Type
Standard
Back to Health Canada Approvals